Association of C-reactive protein/albumin ratio with mortality in patients with Traumatic Brain Injury: A systematic review and meta-analysis
Yuyang Liu,
Yaheng Tan,
Jun Wan,
Qiwen Chen,
Yuxin Zheng,
Wenhao Xu,
Peng Wang,
Weelic Chong,
Xueying Yu,
Yu Zhang
Affiliations
Yuyang Liu
Center for Evidence-based Medicine, Affiliated Hospital of Chengdu University, Chengdu, Sichuan, China; Department of Critical Care Medicine, Affiliated Hospital of Chengdu University, Chengdu, Sichuan, China
Yaheng Tan
Public Health Clinical Center of Chengdu, Chengdu, Sichuan, China
Jun Wan
Center for Evidence-based Medicine, Affiliated Hospital of Chengdu University, Chengdu, Sichuan, China
Qiwen Chen
Department of Critical Care Medicine, Affiliated Hospital of Chengdu University, Chengdu, Sichuan, China
Yuxin Zheng
Department of Critical Care Medicine, Affiliated Hospital of Chengdu University, Chengdu, Sichuan, China
Wenhao Xu
Center for Evidence-based Medicine, Affiliated Hospital of Chengdu University, Chengdu, Sichuan, China; Department of Critical Care Medicine, Affiliated Hospital of Chengdu University, Chengdu, Sichuan, China
Peng Wang
West China Hospital, Sichuan University, Chengdu, Sichuan, China
Weelic Chong
Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA, USA
Xueying Yu
Department of Critical Care Medicine, Affiliated Hospital of Chengdu University, Chengdu, Sichuan, China
Yu Zhang
Center for Evidence-based Medicine, Affiliated Hospital of Chengdu University, Chengdu, Sichuan, China; Corresponding author. Center for Evidence-based Medicine, Affiliated Hospital of Chengdu University, Chengdu University, Chengdu, Sichuan, China.
Objective: This study examines the C-reactive protein (CRP)/albumin ratio (CAR) as an inflammation-based prognostic score for predicting mortality in patients with Traumatic Brain Injury (TBI). Methods: We systematically searched the electronic databases PubMed, Embase, and Cochrane up to February 2024. Our inclusion criteria encompassed studies investigating CAR-predicted mortality in patients with TBI. We calculated the Odds Ratio (OR) and associated 95 % confidence intervals (95 % CI) using a random-effects model. Quality assessment of the included studies was appraised using a Newcastle–Ottawa scale. Results: A total of five studies comprising 1040 patients were included in this meta-analysis. The pooled results indicated that CAR was associated with mortality in patients with TBI (OR = 1.88, 95 % CI: 1.05–3.36, P < 0.0001). The findings of subgroup analysis indicated that the relationship between CAR and mortality in patients with TBI did not vary with the severity of the condition. Conclusions: CAR emerges as a valuable prognostic tool for mortality in patients with TBI, underscoring its potential role in early risk stratification and management strategies.
